Rossari Biotech · NSE: ROSSARI · BSE: 543213
Q4 FY21 results · Jan–Mar 2021
Rossari Biotech reported revenue from operations of ₹218.22 crore and net profit of ₹22.20 crore for Q4 FY21 (Jan–Mar 2021), on a consolidated basis.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 218.22 | — | — | 209.98 | +3.9% |
| Other income | 2.88 | — | — | 0.76 | +280.8% |
| Total income | 221.10 | — | — | 210.74 | +4.9% |
| Profit before tax | 29.91 | — | — | 28.38 | +5.4% |
| Net profit for the period | 22.20 | — | — | 21.62 | +2.7% |
| Attributable to shareholders of the company | 22.43 | — | — | 21.60 | +3.8% |
| EPS, basic (₹) | 4.32 | — | — | 4.16 | +3.8% |
| Net margin (%) | 10.2 | — | 10.3 |
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 201.48 | — | — | 205.76 | −2.1% |
| Other income | 2.54 | — | — | 1.10 | +130.1% |
| Total income | 204.02 | — | — | 206.86 | −1.4% |
| Profit before tax | 29.22 | — | — | 27.29 | +7.1% |
| Net profit for the period | 21.40 | — | — | 20.64 | +3.7% |
| EPS, basic (₹) | 4.12 | — | — | 3.98 | +3.5% |
| Net margin (%) | 10.6 | — | 10.0 |
Consolidated
- Filed with BSE
- 15 May 2021, 12:00 IST
- Board meeting
- 14 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 15 May 2021, 12:00 IST
- Board meeting
- 14 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE